• ATG-101 was developed by introducing lower affinity 4-1BB scFv into a human IgG1 PD-L1 monoclonal antibody. (onclive.com)
  • Furthermore, LAE113 has demonstrated a synergistic effect when combined with LAE005, an anti-PD-L1 monoclonal antibody, in enhancing IFN-γ secretion from CD8+T cells. (laekna.com)
  • Its preclinical program, CTIM-76, is an anti-Claudin 6 x anti-CD3 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAb) that is intended to redirect. (stockhouse.com)
  • When monoclonal antibody technology became generally available in 1978, John Shively, Ph.D., in Todd's lab, produced a Mab to CEA that after genetic engineering and radiolabeling went into City of Hope patients as both an imaging and therapeutic agent. (cityofhope.org)
  • Monoclonal antibody manufacturing is a highly templated approach used to produce mAb-based immunotherapies. (sigmaaldrich.com)
  • We characterize gB-specific monoclonal antibodies isolated from individuals vaccinated with a disabled infectious single cycle (DISC) CMV vaccine, V160, and compare these to the gB-specific monoclonal antibody repertoire isolated from naturally-infected individuals. (bvsalud.org)
  • Tumors were pretargeted with the bispecific monoclonal antibody (bs-mAb) G250xDTIn-1 and, 72 h later, mice were injected intravenously with one of both radiolabeled peptides. (snmjournals.org)
  • In this approach a nonradiolabeled bispecific monoclonal antibody (bs-mAb) with antitumor-associated antigen (TAA) and antihapten specificity is injected in the first phase. (snmjournals.org)
  • This is the first peer-reviewed publication to describe an agonist monoclonal antibody, which triggers pro-resolutive mechanisms in macrophages and neutrophils in chronic inflammatory condition. (pharmiweb.com)
  • COPENHAGEN, DENMARK AND BOSTON, MASS., US - June 24, 2023 - Hemab Therapeutics , a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced results today from preclinical research of HMB-001 in models of factor VII (FVII) deficiency at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress in Montreal. (healthcap.eu)
  • Based in the US and Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. (healthcap.eu)
  • We employ cutting-edge technology platforms to advance the discovery of novel antibody therapeutics. (biocytogen.com)
  • It is an exciting time for the field of bispecific and multispecific therapeutics with candidates like ZW25 demonstrating great promise in clinical trials," said Ali Tehrani, Ph.D., President and CEO of Zymeworks. (pharmalive.com)
  • Azymetric therapeutics have been engineered to retain the desirable drug-like qualities of naturally occurring antibodies, including low immunogenicity, long half-life and high stability. (pharmalive.com)
  • First-generation immuno-oncological antibody therapeutics involved checkpoint modulators targeting common T-cell checkpoints such as PD-1 and CTLA-4. (news-medical.net)
  • Therapeutics of this nature capitalize on the exquisite specificity of antibody biologics to directly target tumor cells with cytotoxic agents (for example, ADCs) or indirectly target tumor cells by actively recruiting other immune cells (such as T-cells and macrophages) via multi-specific antibody formats. (news-medical.net)
  • Need data for other antibody therapeutics that have received marketing authorizations? (antibodysociety.org)
  • Go to our searchable table of approved antibody therapeutics and those in regulatory review for more information. (antibodysociety.org)
  • The ability to tailor antibody functions using modern engineering approaches has ushered in a new wave of bi- and multi-specific antibody therapeutics that unlock novel target classes, biology, and mechanisms of action for the treatment of human diseases. (antibodysociety.org)
  • The reviews should narrate the current state of the art in bi- and multi-specific antibody therapeutics, challenges and opportunities, and speculate on new vistas for the field. (antibodysociety.org)
  • Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. (swingtradebot.com)
  • Nov 2, 2023 - Laekna (2105.HK), a clinical-stage biotechnology company dedicated to bringing novel therapies to cancer and liver fibrosis patients worldwide, today announced that the company will present two new preclinical candidates discovered in house at the 2023 Society for Immunotherapy of Cancer (SITC 2023) in November 1-5, 2023, in San Diego, California. (laekna.com)
  • We are delighted to share the preclinical data for these two promising molecules discovered at Laekna during SITC 2023. (laekna.com)
  • ATG-101 is a novel bispecific antibody that dually targets PD-L1 and 4-1BB. (onclive.com)
  • Currently, the novel bispecific antibody is present in various monotherapy and combination studies. (researchandmarkets.com)
  • Zymeworks' lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. (biotalent.ca)
  • Small-molecule inhibitors, antagonistic monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), bispecific antibodies or biologics (bsAbs) and chimeric antigen receptor-modified T cells (CAR-Ts) targeting Notch signaling components have been developed as investigational anti-cancer drugs ( 10 - 12 ). (spandidos-publications.com)
  • Antibody-drug conjugation (ADC) technology uses monoclonal antibodies (mAbs) to deliver potent, highly active pharmaceutical ingredients (HPAPIs) to targeted cells. (sigmaaldrich.com)
  • We recently reported a novel role of discoidin domain-containing receptor 1 (DDR1) in promoting IE in breast cancer and validated its critical role in IE using neutralizing rabbit monoclonal antibodies (mAbs) in multiple mouse tumor models. (bvsalud.org)
  • Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic cancer products. (biospace.com)
  • Monoclonal antibodies (mAbs) directed against tumor-associated antigens have excellent characteristics to target tumor cells selectively ( 1 - 3 ). (snmjournals.org)
  • NantiBody to develop a phase III antibody from NantCell and a portfolio of preclinical immune-modulating, immuno-oncology and bispecific antibodies as well as ADCs from Sorrento. (centerwatch.com)
  • Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. (biotalent.ca)
  • The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. (swingtradebot.com)
  • The company has made significant advances in developing human monoclonal antibodies, complemented by comprehensive and fully integrated bispecific antibody and antibody drug conjugate (ADC) platforms that include proprietary conjugation chemistries, linkers and toxic payloads. (prnewswire.com)
  • Zymeworks' second candidate, ZW49, is a bispecific antibody-drug conjugate (ADC) and is expected to be the subject of an Investigational New Drug (IND) filing in 2018. (biotalent.ca)
  • Zymeworks' second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks' proprietary ZymeLink™ linker-cytotoxin. (pharmalive.com)
  • By linking with an antibody against Claudin 18.2, a gastric- and pancreatic-specific cancer antigen, TJ-CD4B/ABL111 is uniquely structured to supercharge T cells in a Claudin 18.2-dependent manner, enhancing anti-tumor immunity while potentially minimizing toxicity. (i-mabbiopharma.com)
  • Recently, Janssen Pharmaceutical has developed Teclistamab which is an investigational, fully humanized, T-cell redirecting, IgG4 bispecific antibody targeting both BCMA (B-cell maturation antigen) and CD3, the T-cell receptor. (researchandmarkets.com)
  • Data highlight the potentiality of this novel immunotherapy strategy where a nonspecific cytotoxic cell population can be converted into tumor-specific effectors with clinical-grade antibodies, thus providing not only a therapeutic option for TNBC but also a valid alternative to more complex approaches based on chimeric antigen receptor-engineered cells. (wikipedia.org)
  • Earlier clinical studies reported a high sensitivity of pretargeted immunoscintigraphy using murine or chimeric anticarcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and peptides labeled with 111 In or 131 I in medullary thyroid carcinoma (MTC). (snmjournals.org)
  • Yoneyama T, Kim M-S, Piatkov K, Wang H, Zhu AZX (2022) Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma. (springer.com)
  • Now we have game-changing T-cell-redirecting therapies, such as CAR [chimeric antigen receptor] T-cell therapies and bispecific antibodies," he explained. (onclive.com)
  • This bispecific antibody was developed by Roche using the 2:1 CrossMab technology, characterized by 3 antigen-binding fragment (Fab) arms enabling monovalent binding to CD3ɛ and bivalent binding to CD20, with the second CD20 arm fused to the CD3ɛ-binding arms via a flexible linker. (antibodysociety.org)
  • The most frequently used engagers are antibodies targeting one tumor antigen and one molecule on T cells (mostly CD3). (msdmanuals.com)
  • Additional innovative therapeutic approaches include bispecific antibodies and immunocytokines. (cityofhope.org)
  • In addition to conventional antibodies, the Company's technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. (biospace.com)
  • Data to be presented include studies on the significant reduction in tumor burden and enhanced survival following Cynviloq intraperitoneal therapy, compared to albumin-bound paclitaxel* intravenous therapy in a metastatic model of ovarian cancer, successful development of anti-cancer antibody drug conjugates using novel C- and K-lock linker technology, and significant efficacy of its c-Met/EGFR Bispecific Targeting ADC in a non-small cell lung cancer model. (prnewswire.com)
  • Bispecific/Biparatopic and multispecific/multiparatopic targeting beyond antibodies (Antibody drug conjugates, antibody cytokine fusions, CAR-T/NK/M therapies, ProTACs etc) in various therapeutic areas. (antibodysociety.org)
  • Arvedson T, Bailis JM, Britten CD, Klinger M, Nagorsen D, Coxon A et al (2022) Targeting solid tumors with bispecific T cell engager immune therapy. (springer.com)
  • Treatment of HBV-infected humanized mice with our T-cell engager antibodies resulted in efficient recruitment of human CD4+ and CD8+ T cells into the liver and triggered an effective antiviral immune response", she added. (weeklyreviewer.com)
  • For instance, Xencor and Janssen Biotech have entered an exclusive collaboration and global license agreement for the development and commercialization of plamotamab and XmAb CD28 bispecific antibody combinations to treat patients with B-cell malignancies. (researchandmarkets.com)
  • We are delighted to collaborate with Janssen's leading scientists to expand the scope of the plamotamab program, particularly as we explore opportunities to combine with novel B-cell targeted CD28 bispecific antibodies that can potentially selectively enhance T-cell cytotoxic activity," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. (pharmiweb.com)
  • Further, Xencor will apply its XmAb bispecific Fc technology to create and characterize XmAb CD28 bispecific antibody candidates against B-cell targets during a two-year joint research collaboration, and Janssen will have an exclusive worldwide license to develop selected molecules in combination with plamotamab and other agents, such as CD3 bispecific antibodies. (pharmiweb.com)
  • Xencor will be eligible to receive up to $1.188 billion in potential development, regulatory and sales milestone payments, as well as tiered royalties on net sales of products developed under the agreement, ranging from mid-teen to low-twenties percentages for products containing plamotamab and plamotamab/CD28 bispecific antibody combinations. (pharmiweb.com)
  • Separate terms apply to CD28 bispecific antibodies commercialized outside of a plamotamab combination, where Xencor retains an option to co-fund development costs in exchange for higher royalties and the right to co-detail such products in the United States. (pharmiweb.com)
  • In the study presented, HBV-infected dual humanized mice received a combination of anti-HBs×CD3 and anti-HBs×CD28 antibodies, and after treatment, serum markers, including HBV DNA, HBsAg, and HBeAg, were significantly reduced. (weeklyreviewer.com)
  • To facilitate optimal local T-cell re-direction and activation, two novel T cell-engaging bispecific antibodies, anti-HBs×CD3 and anti-HBs×CD28, have been designed to bridge HBV-infected cells with CD3-expressing and CD28-expressing T cells. (weeklyreviewer.com)
  • The rationale behind the combination of CD3 and CD28 bispecific antibodies stems from the requirement of T cells for dual signalling to achieve full activation. (weeklyreviewer.com)
  • In short span of time, the cumulative sales of the bispecific antibodies have surpassed US$ 9 Billion by first quarter of 2022, thus showing high adoption rates. (researchandmarkets.com)
  • Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. (nih.gov)
  • We leverage a number of proprietary immunization strategies for tough target antibody discovery along with a suite of premium downstream characterization assays to ultimately deliver a panel of fully characterized lead molecules ready for development. (news-medical.net)
  • The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors. (stockhouse.com)
  • Atreca's unique platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. (pmwcintl.com)
  • Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. (swingtradebot.com)
  • Dr. Henry Ji, president and CEO of Sorrento, said, "Through these strategic alliances, we are accelerating the development of our diverse portfolio of fully human monoclonal antibodies into the clinic. (centerwatch.com)
  • Our suite of best-in-class fully human antibody mice de-risk your therapeutic antibody discovery. (biocytogen.com)
  • Abveris is a contract research organization specializing in critical reagent and therapeutic antibody discovery for a wide range of targets, including those in the immune-oncology research space. (news-medical.net)
  • Both drug candidates have demonstrated superior efficacy compared to existing competitors and worked well in combination with anti-PD-1/PD-L1 antibodies to reverse anti-PD-1/PD-L1 antibody resistance. (laekna.com)
  • Laekna now has several promising preclinical candidates entering into IND-enabling studies. (laekna.com)
  • VANCOUVER, British Columbia-( BUSINESS WIRE )-Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks' Azymetric™ and EFECT™ platforms. (pharmalive.com)
  • Our traditional hybridoma discovery approach triages antibody candidates in a high-throughput manner by specificity, affinity, and oftentimes functionality early in the workflow. (news-medical.net)
  • Research and development expenses increased to $5.4 million for the three months ended March 31, 2021 from $4.0 million for the three months ended March 31, 2020 as we continue to invest in the APVO436 clinical trial and our preclinical candidates, including ALG.APV-527, APVO603 and APVO442. (accesswire.com)
  • Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. (swingtradebot.com)
  • With ADCs it is important to look beyond drug-to-antibody ratio (DAR). (sigmaaldrich.com)
  • Under the terms of the new research and license agreement, Zymeworks will provide Merck a worldwide, royalty-bearing license to research, develop and commercialize up to three new multispecific antibodies toward Merck's therapeutic targets. (pharmalive.com)
  • Merck will also receive a worldwide, royalty-bearing license to research, develop and commercialize up to three multispecific antibodies in the animal health field in exchange for additional milestone payments and tiered royalties. (pharmalive.com)
  • The Azymetric platform enables the transformation of monospecific antibodies into bispecific and multispecific antibodies, allowing simultaneous binding to several different disease targets. (pharmalive.com)
  • Reviews on multispecific antibodies (beyond bispecifics i.e., more than two binding epitopes) and their applications. (antibodysociety.org)
  • Reviews on bispecifics and multispecific antibodies beyond oncology (i.e., neurology, infectious disease, ophthalmology, rare diseases etc. (antibodysociety.org)
  • TJ-CD4B is from I-Mab's emerging bispecific antibody portfolio designed to create novel drug molecules that synergize two pathways for better clinical efficacy. (i-mabbiopharma.com)
  • The pre-clinical validation of TJ-CD4B/ABL111 to be presented at AACR signifies the overall progress of I-Mab's bispecific antibody portfolio, reflecting Company's discovery and CMC capabilities to engineer novel molecules with combined target specificities. (i-mabbiopharma.com)
  • These data clearly demonstrate the synergistic effect of small recombinant bispecific molecules recruiting different populations of human effector cells to the same tumor target. (scienceopen.com)
  • The use of antibodies as therapeutic drugs has significantly shifted the landscape of treatment in many areas of medicine including oncology, viral infections and auto-immune diseases. (researchandmarkets.com)
  • Saber H, Del Valle P, Ricks TK, Leighton JK (2017) An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. (springer.com)
  • Betts A, van der Graaf PH (2020) Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. (springer.com)
  • The growing trend of implementing immunotherapy into oncology has resulted in a variety of new therapeutic modalities for cancer treatment options, many of which capitalize on the use of antibodies. (news-medical.net)
  • Jiang X, Chen X, Carpenter TJ, Wang J, Zhou R, Davis HM et al (2018) Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents. (springer.com)
  • Small‑molecule γ‑secretase inhibitors (AL101, MRK‑560, nirogacestat and others) and antibody‑based biologics targeting Notch ligands or receptors [ABT‑165, AMG 119, rovalpituzumab tesirine (Rova‑T) and others] have been developed as investigational drugs. (spandidos-publications.com)
  • Zymeworks' technology plays a significant role in our efforts to identify and develop multispecific antibody therapies," said Scott Lesley, Ph.D., Vice President of Discovery Biologics, Merck Research Laboratories. (pharmalive.com)
  • RenNano-derived antibodies can infiltrate tumor tissues, cross the blood-brain barrier, or be constructed into other therapies. (biocytogen.com)
  • BiTE ® antibodies are novel recombinant single chain Ig domain constructs that leverage the endogenous cytotoxic potential of polyclonal T cells to target malignant cells by utilizing the specific binding properties of variable domains from two different antibodies. (biomedcentral.com)
  • They are generated by ex vivo incubation of human peripheral blood mononuclear cells (PBMC) or cord blood mononuclear cells with interferon-gamma (IFN-γ), anti-CD3 antibody, recombinant human interleukin (IL)-1 and recombinant human interleukin (IL)-2. (wikipedia.org)
  • Preclinical studies showed that new-generation humanized recombinant anti-CEA × antihistamine-succinyl-glycine (HSG) trivalent BsMAb TF2 and radiolabeled HSG peptide (IMP288) present good features for PET. (snmjournals.org)
  • Since 2017, bispecific antibodies have rapid been developed and granted approval to target the chronic diseases owing to their high efficacy and ability to target the multifactorial nature of the disease. (researchandmarkets.com)
  • Transaminase and serum cytokine levels were monitored to determine the preclinical safety of YH006 in vivo . (bmj.com)
  • Antibody-based immunotherapy represents a promising strategy in cancer. (biomedcentral.com)
  • Given the anti-leukemia activity of single-agent Blinatumomab in a difficult-to-treat population with r/r ALL, another BiTE ® antibody targeting CD33, AMG 330, was developed for its suitability as immunotherapy in AML. (biomedcentral.com)
  • Clinical experience with Blinatumomab in ALL and ex-vivo activity of AMG 330 in primary AML samples supports further development of BiTE ® antibodies for targeted T cell-mediated immunotherapy of patients with malignancies. (biomedcentral.com)
  • New model systems are being developed to test and optimize various immunotherapy strategies, including bispecific antibodies, checkpoint inhibitors, epigenetic modifiers and adoptive T cell transfer both in vitro and in vivo. (upenn.edu)
  • T-cell engaging bispecific antibodies present a promising strategy for cancer immunotherapy and numerous bispecific formats have been developed for retargeting cytolytic T cells toward tumor cells. (biorxiv.org)
  • Administration of exogenous antibodies constitutes passive humoral immunotherapy. (msdmanuals.com)
  • The CAR.TNK technology platform combines Conkwest's proprietary Neukoplast cell line with Sorrento's proprietary G-MAB® fully human antibody technology and CAR designs to further enhance the potency and targeting of Neukoplast. (prnewswire.com)
  • Even more precise targeting is on the horizon: for example, technologies that limit antibody activity to the tumor microenvironment and reduce cytotoxic activity in healthy tissue, resulting in a holistic attack on tumor cells with minimal adverse effects. (news-medical.net)
  • Due to our unique combination of engineered mouse models, proprietary immunization techniques, and premium high-throughput and high-content screening capabilities, we specialize in high homology targets, constrained epitope targeting, and tough cell surface targets, all of which exist within the immuno-oncological antibody research space. (news-medical.net)
  • Overview of bispecific and multispecific antibody platforms (includes but not limited to Fc engineering, heavy and light chain pairing methodologies, high throughput production methods, geometrical and valency considerations etc. (antibodysociety.org)
  • It has exhibited superior potency compared to dual antibody NGM707 against LILRB1/2 and other anti-LILRB1, anti-LILRB2 antibodies currently in clinical development. (laekna.com)
  • I-Mab plans to advance more novel bispecific antibodies towards clinical development stage, following the lead of TJ-CD4B/ABL111. (i-mabbiopharma.com)
  • The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven preclinical and clinical development expertise, and world-class GMP manufacturing capabilities. (i-mabbiopharma.com)
  • Zymeworks' lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. (pharmalive.com)
  • The most advanced BiTE ® antibody, Blinatumomab, directs cytotoxic T cells to CD19-expressing target cells. (biomedcentral.com)
  • T-cell engagers are bispecific antibodies that recruit cytotoxic T cells to kill tumor cells. (msdmanuals.com)
  • Two investigational BiTE antibodies are under development targeting leukemia. (biomedcentral.com)
  • LAE 111 is a novel and potent bispecific antibody targeting LILRB1 and LILRB2. (laekna.com)
  • Bispecific antibodies are dual targeting modalities and can simultaneously combine two epitopes. (researchandmarkets.com)
  • Other current efforts include the exploration of immunomodulation to potentiate endogenous antitumor T cell responses, use of bispecific antibodies, pharmacological sensitization of tumor cells to immune attack, tumor vasculature targeting, preclinical validations, clinical translation and trial support. (upenn.edu)
  • To explore the therapeutic utility of T-cell engaging bispecific antibodies targeting the receptor tyrosine kinase ROR1, which is expressed by tumor cells of various hematologic and solid malignancies, we used a bispecific ROR1 × CD3 scFv-Fc format based on a heterodimeric and aglycosylated Fc domain designed for extended circulatory half-life and diminished systemic T-cell activation. (biorxiv.org)
  • A diverse panel of ROR1-targeting scFv derived from immune and naïve rabbit antibody repertoires was compared in this bispecific format for target-dependent T-cell recruitment and activation. (biorxiv.org)
  • A ROR1-targeting scFv with a membrane-proximal epitope, R11, revealed potent and selective antitumor activity in vitro and in vivo and emerged as a prime candidate for further preclinical and clinical studies. (biorxiv.org)
  • The next step will be to identify antibody sequences that break down the amyloid beta, and to introduce mutations that increase the activity and targeting of the antibody so that it breaks down amyloid beta but not other proteins. (brightfocus.org)
  • Glofitamab (RO7082859) is a full-length IgG1λ/ҡ bispecific T cell redirecting antibody targeting CD20 on malignant B cells and CD3 on T cells. (antibodysociety.org)
  • Antibodies targeting two tumor antigens and CD3 are being tested. (msdmanuals.com)
  • BiTE ® antibodies have demonstrated efficacy in hematologic malignancies, both preclinically and clinically. (biomedcentral.com)
  • Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y et al (2015) Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. (springer.com)
  • Plamotamab is a CD20 x CD3 XmAb bispecific antibody and is currently completing a Phase 1 dose-escalation study in patients with CD20-expressing hematologic malignancies. (pharmiweb.com)
  • Additionally, it is a universal ADCC enhancer when combined with monoclonal antibodies and NK cell engagers. (laekna.com)
  • Since tumor-infiltrating Treg cells consistently exhibit higher expression levels of both CTLA-4 and OX40 compared to T cells in the periphery across multiple cancer types, 4 5 we developed an Fc-enhanced CTLA-4×OX40 bispecific IgG1 antibody, YH006, designed to deplete tumor-infiltrating Treg cells with better specificity. (bmj.com)
  • Zanidatamab is a novel HER2-targeted bispecific antibody with biparatopic binding and the potential to transform the current standard of care in multiple HER2 expressing cancers," said Rob Iannone , M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. (zymeworks.com)
  • Antibodies derived from RenLite mice against 200+ TAA targets are available for BsADC generation. (biocytogen.com)
  • 1 2 Although the first generation Treg-depleting CTLA-4 antibody ipilimumab has shown clinical efficacy, its use, particularly in combination with PD-1 inhibitors, has been associated with severe immune-related adverse events. (bmj.com)
  • However, CIK cells have the ability to recognize infected or even malignant cells in the absence of antibodies and MHC, allowing for a fast and unbiased immune reaction. (wikipedia.org)
  • The EFECT platform is a library of antibody Fc modifications engineered to activate or suppress the antibody-mediated immune response. (pharmalive.com)
  • Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution " (1) reports on the discovery and preclinical data for OSE-230, an innovative agonist antibody against ChemR23, also known as chemerin chemokine-like receptor 1 (CMKLR1), a G-protein coupled receptor (GPCR) expressed on myeloid immune cells known to modulate inflammation. (pharmiweb.com)
  • Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. (mpg.de)
  • This includes engineered radiolabeled antibodies for immunoPET imaging and radioimmunotherapy, in preclinical models as well as translation into pilot and phase I clinical trials. (cityofhope.org)
  • The humanized antibody named PRTH-101 is currently being tested in a Phase 1 clinical trial. (bvsalud.org)
  • The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. (swingtradebot.com)
  • Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen offers solutions for preclinical antibody drug discovery and efficacy validation. (biocytogen.com)
  • ATG-101, a novel PD-L1/4-1BB bispecific antibody, demonstrated good in vivo efficacy, safety without hepatotoxicity, and pharmacokinetic/pharmacodynamic properties in cynomolgus monkeys, according to preclinical findings from a study presented in a poster during the 2021 SITC Annual Meeting . (onclive.com)
  • Indeed, the engagement of CD16a on CD3+CD56+ cells led to a potent antibody-dependent cell-mediated cytotoxicity (ADCC) both in vitro and in vivo against ovarian cancer. (wikipedia.org)
  • CTIM-76 is a Claudin 6 and CD3 bispecific antibody capable of binding to tumor cells expressing Claudin 6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement. (stockhouse.com)
  • The treatment landscape in B-cell lymphoma will potentially be redefined by CD20 x CD3 bispecific antibodies, such as plamotamab, and the best outcomes for patients will require creative combination approaches using complementary mechanisms of action. (pharmiweb.com)
  • ATG-101, a novel PD-L1/4-1BB bispecific antibody, demonstrated good in vivo efficacy, safety without hepatotoxicity, and pharmacokinetic/pharmacodynamic properties in cynomolgus monkeys. (onclive.com)
  • In vivo syngeneic tumor studies demonstrated a superior and dose-dependent anti-tumor activity of YH006 compared to both ipilimumab analog and its Fc-enhanced parental monoclonal antibodies at low doses. (bmj.com)
  • The preclinical research presented at ISTH, "HMB-001, a Bispecific anti-FVIIa/anti-TLT-1 Antibody Demonstrates Effect in Models of FVII Deficiency,"assessed key requirements for HMB-001 to function in FVII deficiency, specifically its ability to bind with FVII protein variants associated with moderate/severe deficiency and the potential of HMB-001 to accumulate FVIIa in an in-vivo non-human primate model of FVII deficiency. (healthcap.eu)
  • Extracted cells are ex-vivo exposed to interferon-gamma, anti-CD3 antibody, interleukin-1 and interleukin-2 in a time-sensitive schedule. (wikipedia.org)
  • Comprehensive preclinical PK/PD, in vivo, and in vitro evaluation of novel test articles. (biocytogen.com)
  • Immunized RenMice undergo in vivo selection and affinity maturation to generate quality antibody hits. (biocytogen.com)
  • Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. (scienceopen.com)
  • 3 To address this difficulty, we set out to develop a next-generation Treg-depleting antibody with improved efficacy and safety. (bmj.com)
  • The preclinical profile highlights its outstanding potential as a best-in-class candidate with favorable drug like properties for development. (laekna.com)
  • The growing interest in the therapeutic antibodies along with the rapid progress in antibody engineering has enabled the development of wide range of bispecific formats. (researchandmarkets.com)
  • Our RenLite ® model contains a fixed common light chain that eliminates chain mispairing during bispecific antibody development. (biocytogen.com)
  • In his role as Chief Strategy Officer, Dr. Serafini is responsible directly for research, preclinical development, technology, and intellectual property. (pmwcintl.com)
  • The results from our first-in-class preclinical PoC study give us confidence in our bispecific development program for infectious diseases, and we eagerly anticipate further exploration and investigation. (weeklyreviewer.com)
  • Furthermore, the combination of LAE111 with an anti-PD-1/PD-L1 antibody markedly activated T cell response, giving it the potential to become a novel cancer therapy to overcome PD-1/PD-L1 resistance. (laekna.com)
  • Apart from this, 6 other bispecific antibodies have gained market authorization for various indications including Hemlibra for hemophilia, Blincyto for acute lymphoblastic leukemia, Rybrevant for non-small cell lung cancer, Vabysmo for Neovascular (Wet) Age‑related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), Cadonilimab for cervical cancer, and Lunsmio for follicular lymphoma. (researchandmarkets.com)
  • It has been shown that lymphocytes, when exposed to interferon-gamma, anti-CD3 antibody, interleukin-1 and interleukin 2, are capable of lysing fresh, non-cultured cancer cells, both primary and metastatic. (wikipedia.org)
  • Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. (springer.com)
  • It has also demonstrated exceptional stability and developability in preclinical setting. (laekna.com)
  • The presentation will feature preclinical data of two bispecific antibodies, LAE111, an anti-LILRB1/LILRB2 bispecific antibody modulating myeloid, NK and T cell functions, and LAE113, an anti-PVRIG/TIGIT bispecific antibody modulating T cell and NK cell functions. (laekna.com)
  • For example, there were no T cell subsets and antibodies were all polyclonal. (cityofhope.org)
  • We find that vaccination with V160 resulted in gB-specific antibodies that bound homogenously to gB expressed on the surface of a cell in contrast to antibodies isolated from natural infection which variably bound to cell-associated gB. (bvsalud.org)
  • Our approach demonstrates that T cells activated by antibodies can efficiently target the nuclear cccDNA reservoir despite high levels of baseline circulating HBsAg. (weeklyreviewer.com)